A RANDOMIZED, PROSPECTIVE, DOUBLE-BLINDED TRIAL OF CYCLOSPORINE VS. OG37–325 IN CADAVERIC RENAL TRANSPLANTATION—A PRELIMINARY REPORT

Publisher Website
Google Scholar
Abstract
The efficacy of cyclosporine is documented, but it has side effects that are troublesome. Another compound, OG37-325, has been identified that appears to have similar efficacy, but less nephrotoxicity. This study was designed to address the benefits and toxicities of cyclosporine and OG37-325 in a prospective, randomized, double-blinded trial in cadaveric renal transplant recipients. The preliminary results demonstrate similar outcomes in terms of patient and graft survival, but suggest less nephrotoxicity in the OG37-325-treated patients. Longer follow-up will delineate the utility of OG37-325 in solid-organ transplantation.

This publication has 0 references indexed in Scilit: